title: Computed tomography screening for lung cancer in Hodgkin's lymphoma survivors: decision analysis and cost-effectiveness analysis.
abstract: BACKGROUND
  Hodgkin's lymphoma patients have an elevated risk of developing lung cancer and may be targeted for lung cancer screening. We used a decision-analytic model to estimate the potential clinical benefits and cost-effectiveness of computed tomography (CT) screening for lung cancer in Hodgkin's lymphoma survivors.
  
  
  METHODS
  We developed a Markov decision-analytic model to compare annual low-dose CT screening versus no screening in a hypothetical cohort of patients diagnosed with stage IA-IIB Hodgkin's lymphoma at age 25, with screening starting 5 years after initial diagnosis. We derived model parameters from published studies and the Surveillance, Epidemiology and End Results (SEER) Program, and assumed that stage-shift produces a survival benefit.
  
  
  RESULTS
  Annual CT screening increased survival by 0.64 years for smokers and 0.16 years for non-smokers. The corresponding benefits in quality-adjusted survival were 0.58 quality-adjusted life-years (QALYs) for smokers and 0.14 QALYs for non-smokers. The incremental cost-effectiveness ratios for annual CT screening compared with no screening were $34 100/QALY for smokers and $125 400/QALY for non-smokers.
  
  
  CONCLUSIONS
  Our analysis suggests that if early promising results for lung cancer screening hold, CT screening for lung cancer may increase survival and quality-adjusted survival among Hodgkin's lymphoma survivors, with a benefit and incremental cost-effectiveness ratio for smokers comparable to that of other recommended cancer screening strategies.
authors.affiliation: Department of Radiation Oncology, U.T. M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 97, Houston, TX 77030, USA. PrajDas@mdanderson.org
authors.forename: P
authors.initials: P
authors.lastname: Das
authors.forename: A K
authors.initials: AK
authors.lastname: Ng
authors.forename: C C
authors.initials: CC
authors.lastname: Earle
authors.forename: P M
authors.initials: PM
authors.lastname: Mauch
authors.forename: K M
authors.initials: KM
authors.lastname: Kuntz
mesh_terms: D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000191:economics; D018288:Carcinoma, Small Cell / Q000000981:diagnostic imaging / Q000191:economics; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D005260:Female; D006689:Hodgkin Disease / Q000000981:diagnostic imaging*; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000191:economics; D008297:Male; D008390:Markov Chains; D008403:Mass Screening / Q000191:economics*; D008875:Middle Aged; D011788:Quality of Life; D019057:Quality-Adjusted Life Years; D018570:Risk Assessment; D012307:Risk Factors; D018426:SEER Program; D012680:Sensitivity and Specificity; D017741:Survivors; D014057:Tomography, X-Ray Computed / Q000191:economics*